StoneX Group’s Liminatus Pharma LIMN Stock Holding History

StoneX Group’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-521	Closed	-$3.93K	–	2272
2026 Q2	$3.93K	Buy	+521	New	+$4.5K	﹤0.01%	1427

Other funds holding LIMN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

StoneX Group's LIMN Position: Q3 2026 in Review

StoneX Group sold out of Liminatus Pharma (LIMN) in Q3 2026, closing a stake of 521 shares — an estimated $3.93K sold.

StoneX Group first reported a position in LIMN in Q2 2026 and held it in 1 quarter. The position peaked at $3.93K in Q2 2026. 9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

StoneX Group reported no remaining Liminatus Pharma position as of Q3 2026 after selling out during the quarter.
StoneX Group sold 521 Liminatus Pharma shares in Q3 2026, an estimated $3.93K.
StoneX Group first reported a position in Liminatus Pharma in Q2 2026 and held it in 1 quarter.
StoneX Group's Liminatus Pharma position peaked at $3.93K in Q2 2026.
9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.